Description: Magenta Therapeutics Inc is a clinical-stage biotechnology company. It is engaged in developing novel medicines to bring the curative power of bone marrow transplant.
Home Page: www.magentatx.com
MGTA Technical Analysis
100 Technology Square
Cambridge,
MA
02139
United States
Phone:
857 242 0170
Officers
| Name | Title |
|---|---|
| Dr. Jason Gardner DPHIL, Ph.D. | Co-Founder, CEO, Pres & Director |
| Mr. David Wayne Nichols | Chief Technical Officer |
| Mr. Thomas W. Beetham J.D., MBA | Chief Legal Officer & Sec. |
| Mr. Stephen F. Mahoney J.D., MBA | Chief Financial & Operating Officer and Treasurer |
| Dr. Lisa M. Olson Ph.D. | Head of Research & Chief Scientific Officer |
| Mr. Jim Haney | Sr. Director of Investor Relations |
| Lyndsey Scull | Director of Corp. Communications |
| Ms. Kristen Stants | Chief People Officer |
| Ms. Catherine Monaghan | Head of Clinical Devel. Operations |
| Ms. Caren Deardorf | Chief Commercial Officer |
Exchange: NASDAQ
Country: US : United States of America
Currency: US Dollar ($)
| GIC Sector: | Health Care |
|---|---|
| GIC Group: | Pharmaceuticals, Biotechnology & Life Sciences |
| GIC Industry: | Biotechnology |
| GIC Sub-Industry: | Biotechnology |
| Forward PE: | 0 |
|---|---|
| Trailing PE: | 0 |
| Price-to-Book MRQ: | 0.5371 |
| Price-to-Sales TTM: | 0 |
| IPO Date: | 2018-06-21 |
| Fiscal Year End: | December |
| Full Time Employees: | 66 |